**4. Conclusions and Perspectives**

The description of the ferroptosis mode of cell death is still recent. Although its participation in several diseases such as cancer has been increasingly established, in neurodegenerative diseases information is still lacking. Most data have been obtained from experimental studies and more clinical approaches are necessary. For instance, the experimental use of iron chelators and antioxidants has shown to be effective as a possible alternative to interrupt the process of ferroptosis in neurodegenerative diseases. However, when tested in humans, they showed reduced efficacy, which shows that research involving signaling molecules from other pathways that trigger the process of ferroptosis are needed. Nevertheless, there is a growing body of evidence that ferroptosis plays a central role in several neurodegenerative diseases, at least in those described here. This field of research may still yield promising results and disruptive therapeutic alternatives for patients with neurodegenerative diseases.

**Author Contributions:** Conceptualization, C.O.R., D.L., and S.P.B.; writing—original draft preparation C.O.R., F.A.d.F., J.S.-S., L.R.-R., P.d.L.B., D.L., and S.P.B.; writing—review and editing, C.O.R., D.L., and S.P.B.; supervision, S.P.B; funding acquisition, S.P.B. The figures were created by authors using bioBender.com. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was supported by grants from Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq); Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES); Instituto Nacional de Ciência e Tecnologia–Fluidos Complexos (INCT-FCx); Instituto Nacional de Ciência e Tecnologia em Medicina Regenerativa (INCT-Regenera), all from Brazil.

**Conflicts of Interest:** The authors declare no conflict of interest.
